

Table 14.1.1
 Summary of Demographics
 Safety Population

Characteristics	Placebo (N=XX)	Xanomeline Low Dose (N=XX)	Xanomeline High Dose (N=XX)
Age (years)			
n	XX	XX	XX
Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
Median	XX.X	XX.X	XX.X
Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
Min, Max	XX, XX	XX, XX	XX, XX
Age Group, n (%)			
< 65 years	XX (XX.X)	XX (XX.X)	XX (XX.X)
≥ 65 years	XX (XX.X)	XX (XX.X)	XX (XX.X)
Gender, n (%)			
Male	XX (XX.X)	XX (XX.X)	XX (XX.X)
Female	XX (XX.X)	XX (XX.X)	XX (XX.X)
Ethnicity, n (%)			
Hispanic or Latino	XX (XX.X)	XX (XX.X)	XX (XX.X)
Not Hispanic or Latino	XX (XX.X)	XX (XX.X)	XX (XX.X)

Table 14.1.1
 Summary of Demographics
 Safety Population

Characteristics	Treatment X (N=XX)	Treatment Y (N=XX)	Total (N=XX)
Primary Race, n (%)			
American Indian or Alaska Native	XX (XX.X)	XX (XX.X)	XX (XX.X)
Asian	XX (XX.X)	XX (XX.X)	XX (XX.X)
Black or African American	XX (XX.X)	XX (XX.X)	XX (XX.X)
Native Hawaiian or Other Pacific Islander	XX (XX.X)	XX (XX.X)	XX (XX.X)
White	XX (XX.X)	XX (XX.X)	XX (XX.X)
Multiple	XX (XX.X)	XX (XX.X)	XX (XX.X)
Not Reported	XX (XX.X)	XX (XX.X)	XX (XX.X)
Unknown	XX (XX.X)	XX (XX.X)	XX (XX.X)
Other	XX (XX.X)	XX (XX.X)	XX (XX.X)
Height (cm)			
n	XX	XX	XX
Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)
Median	XX.X	XX.X	XX.X
Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X
Min, Max	XX, XX	XX, XX	XX, XX